Gene therapy hope for toddlers with duchenne muscular dystrophy

NCT ID NCT06128564

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 28 times

Summary

This study tests a gene therapy called delandistrogene moxeparvovec in children under 4 with Duchenne muscular dystrophy, a severe muscle-weakening disease. The goal is to see if the treatment is safe and helps produce a key muscle protein. Thirteen children will be followed for about 5 years to monitor side effects and protein levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chr de La Citadelle

    Liège, 3500, Belgium

  • Great Ormond Street Hospital for Children

    London, WC1N 3JH, United Kingdom

  • Hospital Sant Joan De Deu

    Esplugues de Llobregas, Barcelona, 08950, Spain

  • Hôpital Necker-Enfants Malades

    Paris, 75015, France

  • John Radcliffe Hospital

    Oxford, OX3 9DU, United Kingdom

  • PU A. Gemelli, Università Cattolica del Sacro Cuore

    Rome, Lazio, 00168, Italy

  • Universitätsklinikum Essen

    Essen, 45147, Germany

Conditions

Explore the condition pages connected to this study.